Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acquired inhibitors

A J Cohen1, C M Kessler

  • 1St. Michael's Medical Center, Newark, NJ 07102, USA.

Bailliere'S Clinical Haematology
|June 1, 1996
PubMed
Summary
This summary is machine-generated.

Factor VIII auto-antibody inhibitors cause rare but severe bleeding. Treatment varies by inhibitor level and patient condition, including factor concentrates, immunosuppressants, and clinical trials for new therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aging phenotype(s) in kidneys of diabetic mice are p66ShcA dependent.

American journal of physiology. Renal physiology·2018
Same author

Pain in haemophilia: are we listening?

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Methodologies for data collection in congenital haemophilia with inhibitors (CHwI): critical assessment of the literature and lessons learned from recombinant factor VIIa.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Lenalidomide as a novel therapy for gastrointestinal angiodysplasia in von Willebrand disease.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Efficacy and safety of Nuwiq<sup>®</sup> (human-cl rhFVIII) in patients with severe haemophilia A undergoing surgical procedures.

Haemophilia : the official journal of the World Federation of Hemophilia·2017
Same author

Acquired haemophilia in cancer: A systematic and critical literature review.

Haemophilia : the official journal of the World Federation of Hemophilia·2017
Same journal

Current status of stem cell therapy and prospects for gene therapy for the disorders of globin synthesis.

Bailliere's clinical haematology·2000
Same journal

Pharmacological therapy.

Bailliere's clinical haematology·2000
Same journal

Prenatal diagnosis and screening of the haemoglobinopathies.

Bailliere's clinical haematology·2000
Same journal

Sickle cell disease: clinical management.

Bailliere's clinical haematology·2000
Same journal

Pathophysiology of sickle cell disease.

Bailliere's clinical haematology·2000
Same journal

Thalassaemia: clinical management.

Bailliere's clinical haematology·2000
See all related articles

Area of Science:

  • Hematology
  • Immunology

Background:

  • Factor VIII auto-antibody inhibitors are rare but can cause life-threatening hemorrhage.
  • These inhibitors predominantly affect older individuals and are associated with various conditions or can arise spontaneously.
  • They are polyclonal IgG immunoglobulins targeting Factor VIII (FVIII) procoagulant activity.

Purpose of the Study:

  • To review the characteristics, diagnosis, and management of Factor VIII auto-antibody inhibitors.
  • To discuss treatment strategies for acquired inhibitors of other coagulation factors.
  • To highlight the need for further research into novel treatment modalities.

Main Methods:

  • Laboratory diagnosis involves aPTT clotting time, mixing studies, and specific factor assays.
  • Auto-antibody quantification is commonly performed using the Bethesda assay.

Related Experiment Videos

  • Review of existing literature on Factor VIII auto-antibody inhibitor management.

    • Main Results:

    • Treatment approaches are tailored to the underlying condition, inhibitor titer, and clinical presentation.
    • Acute bleeding with high-titer inhibitors may respond to porcine FVIII concentrate, PCCs, or rFVIIa.
    • Low-titer inhibitors may respond to human FVIII concentrate or DDAVP; immunosuppressive therapy is used for long-term reduction.

    Conclusions:

    • Management of Factor VIII auto-antibody inhibitors requires a personalized approach considering various factors.
    • Acquired inhibitors of other coagulation factors share similar management principles.
    • Multicenter randomized clinical trials are essential to evaluate new treatments for coagulation factor inhibitors.